It's not often you come across a true value stock in the pharmaceutical sector. There are more than a few stocks in the sector that come up on a variety of standard value screens -- price-to-cash, price-to-book, NCAV -- but those are generally biotech or early-stage development companies which are burning through significant amounts of their seemingly impressive asset bases.
It's what makes Cumberland Pharmaceuticals (CPIX) so surprising. The stock closed Friday at $4.44 per share, giving it a market capitalization of just under $85 million. Yet the company has some $65 million in cash and securities on its balance sheet, net of its exposure to a small line of credit, putting its enterprise value below $20...
Only subscribers can access this article, which is part of the PRO research library covering 3,770 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: